The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|92|1|112-117

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.92, Iss.1, 2012-07, pp. : 112-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 4, 2014-10 ,pp. : 423-428

John Wiley & Sons Inc

Access to resources Recommend Favorite

SLCO1B1 Genetic Variant Associated With Statin‐Induced Myopathy: A Proof‐of‐Concept Study Using the Clinical Practice Research Datalink

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 695-701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 210-216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 169-174

John Wiley & Sons Inc

Access to resources Recommend Favorite